Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

OZCAN, Muhammet; Dizdar, ÖMER; DINCER, Nazmiye; BALCI, Serdar; Guler, GÜLNUR; GOK, Bahri; PEKTAS, Gokhan; SEKER, Mehmet; AKSOY, SERCAN; Arslan, ÇAĞATAY; Yalcin, ŞUAYİB; BALBAY, Mevlana

doi:10.1016/j.urolonc.2012.06.014

Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

Copy For Citation

OZCAN M. F., Dizdar O., DINCER N., BALCI S., Guler G., GOK B., ...More

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.31, no.8, pp.1709-1715, 2013 (SCI-Expanded)

Publication Type: Article / Article
Volume: 31 Issue: 8
Publication Date: 2013
Doi Number: 10.1016/j.urolonc.2012.06.014
Journal Name: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1709-1715
Hacettepe University Affiliated: Yes

Abstract

Purpose: Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance. Prognostic role of ERCC1 expression in the neoadjuvant setting in bladder cancer has not been reported before. We evaluated the prognostic role of ERCC1 expression in bladder cancer receiving platinum-based neoadjuvant chemotherapy.